Here are the 10-Q quarterly reports from Concentra Group Holdings Parent, Inc. (CON) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CON filings page.
Concentra Group Holdings Parent, Inc. (CON) reported third-quarter revenue of $622.1 million, up 8.6% from $572.8 million. Net income attributable to the company was $65.9 million, versus $48.3 million, and diluted earnings per share were $0.52, versus $0.38. Adjusted EBITDA was $140.2 million, versus $118.9 million. For the first nine months, revenue was $1,797.7 million, up 10.7%, and net income attributable to the company was $181.7 million, versus $131.7 million.
Quarterly patient visits increased 4.9% to 3,731,956; management attributed revenue growth primarily to organic increases in visits and revenue per visit. The 2025 acquisitions of Nova Medical Centers and Pivot Onsite Innovations also contributed to nine-month revenue. Nine-month operating cash flow was $208.1 million, versus $160.7 million. At September 30, 2026, cash was $85.8 million and revolving-credit availability was $430.3 million; Concentra made $50.0 million in voluntary term-loan prepayments during the quarter.
After quarter-end, the board authorized a new share repurchase program of up to $250 million with no expiration date; the authorization does not require repurchases. It also declared a $0.0625-per-share dividend payable on or about December 4, 2026, to holders of record November 19, 2026.
Concentra Group Holdings Parent, Inc. reported higher Q3 results. Revenue reached $572.8 million versus $489.6 million a year ago, and net income attributable to the company was $48.3 million versus $44.3 million. Basic and diluted EPS were $0.38 compared with $0.37.
Year to date, revenue was $1.624 billion versus $1.435 billion, while net income attributable to the company was $131.7 million versus $145.0 million. Operating cash flow was $160.7 million; cash ended at $49.9 million after investing $394.7 million, driven mainly by acquisitions.
The company completed the Nova Medical Centers acquisition for $265.0 million and the Pivot Onsite Innovations acquisition for $54.4 million. Q3 revenue included Nova $31.3 million and Pivot $16.6 million. Debt consisted of $650.0 million 6.875% senior notes and credit facilities including a Term Loan with $945.3 million principal outstanding; the revolver provided $393.0 million availability. The reported leverage ratio was 3.6x. The network operated 628 occupational health centers and 413 onsite clinics as of September 30, 2025.
Concentra Group Holdings Parent, Inc. — Form 10-Q (Quarter ended June 30, 2025)
Q2 2025 revenue rose to $550.8 million versus $477.9 million in Q2 2024 (+~15%). Six-month revenue was $1,051.5 million versus $945.5 million. Despite revenue growth, net income attributable to the company declined to $44.6 million for the quarter (Q2 2024: $51.7 million); EPS fell to $0.35 (Q2 2024: $0.50). Cash declined to $73.9 million from $183.3 million at year-end 2024.
Material corporate actions: acquisition of Nova Medical Centers (closed March 1, 2025) for a preliminary purchase price of $265.0 million and Pivot Onsite Innovations (closed June 1, 2025) for $54.4 million. Goodwill increased materially (preliminary goodwill of $206.96M and $34.43M). Company amended credit facilities (revolver increased to $450M; incremental term loan $102.1M); net leverage was 3.8x (covenant 6.5x). AOCI shows $3.9 million loss from hedges. Significant contingencies include a multi-million patient data-breach class action matter and DOJ inquiry regarding physical therapy billing; outcomes are uncertain. Board declared a $0.0625/share dividend payable Aug 28, 2025.